Kobayashi Pharmaceutical Co Ltd (Kobayashi) manufactures and sells OTC pharmaceuticals, deodorizing air fresheners, and sanitary products. The company manufactures and sells OTC pharmaceuticals, oral hygiene products, food products, deodorizing air fresheners, and sanitary products. It offers medical equipment and devices to medical institutions and general hospitals in Japan. The company also carries out other businesses including transportation, insurance, real estate management, and advertising.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Kobayashi has undertaken several R&D initiatives to strengthen its capabilities and expand its market presence. The company has initiated operations at the new Sendai plant and the Saito R&D and Manufacturing Lab, which are expected to contribute to growth despite increased depreciation and running costs. The strategic pillars for growth include rebuilding trust, fostering corporate transformation, ensuring sustainable growth of domestic business, accelerating global expansion, and implementing capital-efficient management. The company is focusing on optimizing development and marketing resources for its international business and enhancing the quality of new product development within the domestic market. Additionally, Kobayashi Pharmaceutical is investing in future growth businesses and is committed to launching new products that meet customer needs while developing existing products. The financial outlook indicates an expected increase in net sales due to advertising activities and overseas business growth, although operating income is projected to decrease due to increased advertising expenses and costs associated with the new facilities. The R&D units of the company include the new Sendai plant and the Saito R&D and Manufacturing Lab, which are responsible for contributing to the company's growth through research and development activities. In FY2025, the company spent JPY9,122 million on its R&D activities, which as a percentage of revenue stood at 5.5%, and grew 0.1% YoY.